NCT01397864 - C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks | Biotech Hunter

Enrollment

181

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

October 18, 2024

Study Completion Date

December 10, 2024

Conditions

Hereditary Angioedema

Interventions

DRUG

rhC1INH or pdC1INH

C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest)

Trial Locations (17)

UMHAT Alexandrovska EAD, Sofia

KBC Split, Split

General Hospital Sibenik, Šibenik

CHC Sestre milosrdnice, Zagreb

Faculty Hospital by St. Anna Brno, Brno

Hospital A Michallon, CHU Grenoble, La Tronche

Charite Universitatsmedizin Berlin, Berlin

Semmelweis University, 3rd Department of Internal Medicine, Budapest

Ospedale Luigi Sacco, Milan

PHI University Clinic of Dermatology, Skopje

Alesund Hospital, Ålesund

Stavanger University Hospital, Stavanger

University Hospital Krakow, Krakow

Bratislava University Hospital, Bratislava

University Hospital Martin, Martin

University Clinic Golnik, Golnik

Ryhof County Hospital, Jönköping